Su-Jun Deng

502 total citations
7 papers, 399 citations indexed

About

Su-Jun Deng is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Su-Jun Deng has authored 7 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Genetics and 3 papers in Immunology. Recurrent topics in Su-Jun Deng's work include Estrogen and related hormone effects (3 papers), Bioactive Compounds and Antitumor Agents (2 papers) and interferon and immune responses (1 paper). Su-Jun Deng is often cited by papers focused on Estrogen and related hormone effects (3 papers), Bioactive Compounds and Antitumor Agents (2 papers) and interferon and immune responses (1 paper). Su-Jun Deng collaborates with scholars based in United States, United Kingdom and Hungary. Su-Jun Deng's co-authors include Shawn P. Williams, Kevin P. Madauss, Eugene L. Stewart, H. Luke Carter, Eugene T. Grygielko, Scott K. Thompson, Jeffrey D. Bray, Anthony C. Sulpizio, Nicholas J. Laping and Charlene Wu and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Medicinal Chemistry.

In The Last Decade

Su-Jun Deng

7 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Su-Jun Deng United States 6 186 135 50 48 48 7 399
Jamie Arnott United States 8 202 1.1× 67 0.5× 13 0.3× 11 0.2× 20 0.4× 21 442
Nobuo Cho Japan 17 1.0k 5.5× 85 0.6× 23 0.5× 44 0.9× 116 2.4× 27 1.3k
Ayşe Latif United Kingdom 14 227 1.2× 206 1.5× 16 0.3× 9 0.2× 13 0.3× 26 645
Elisabeth Werner Rönnerman Sweden 11 200 1.1× 31 0.2× 12 0.2× 19 0.4× 30 0.6× 23 472
Hitisha Patel United States 8 247 1.3× 295 2.2× 7 0.1× 60 1.3× 11 0.2× 13 654
Sharon Benzeno United States 8 512 2.8× 129 1.0× 23 0.5× 18 0.4× 6 0.1× 13 693
Yeong Sang Kim United States 13 614 3.3× 64 0.5× 24 0.5× 57 1.2× 10 0.2× 17 863
Mark Sales United Kingdom 13 300 1.6× 99 0.7× 93 1.9× 27 0.6× 4 0.1× 15 608
Diana C. West United States 9 292 1.6× 84 0.6× 7 0.1× 39 0.8× 4 0.1× 10 525
Da-Qiang Li China 11 334 1.8× 32 0.2× 25 0.5× 41 0.9× 6 0.1× 19 425

Countries citing papers authored by Su-Jun Deng

Since Specialization
Citations

This map shows the geographic impact of Su-Jun Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Su-Jun Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Su-Jun Deng more than expected).

Fields of papers citing papers by Su-Jun Deng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Su-Jun Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Su-Jun Deng. The network helps show where Su-Jun Deng may publish in the future.

Co-authorship network of co-authors of Su-Jun Deng

This figure shows the co-authorship network connecting the top 25 collaborators of Su-Jun Deng. A scholar is included among the top collaborators of Su-Jun Deng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Su-Jun Deng. Su-Jun Deng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Deng, Su-Jun, Zeyu Chen, & Yuling Shi. (2025). Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases. Cell & Bioscience. 15(1). 137–137. 2 indexed citations
2.
Cao, Shiyun, Hui Shi, Haibin Mao, et al.. (2024). Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress. Cell. 187(26). 7568–7584.e22. 13 indexed citations
3.
Wang, Yonghui, Chaya Duraiswami, Kevin P. Madauss, et al.. (2009). 2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2′,3′:4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 4916–4919. 11 indexed citations
4.
Wayne, Gareth, Su-Jun Deng, Augustin Amour, et al.. (2007). TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4. Journal of Biological Chemistry. 282(29). 20991–20998. 55 indexed citations
5.
Madauss, Kevin P., Eugene T. Grygielko, Su-Jun Deng, et al.. (2007). A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator. Molecular Endocrinology. 21(5). 1066–1081. 125 indexed citations
6.
Hassell, Anne M., Gang An, Randy K. Bledsoe, et al.. (2006). Crystallization of protein–ligand complexes. Acta Crystallographica Section D Biological Crystallography. 63(1). 72–79. 120 indexed citations
7.
Madauss, Kevin P., Su-Jun Deng, Millard H. Lambert, et al.. (2004). Progesterone Receptor Ligand Binding Pocket Flexibility:  Crystal Structures of the Norethindrone and Mometasone Furoate Complexes. Journal of Medicinal Chemistry. 47(13). 3381–3387. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026